BPI-572270 (Not yet branded)

Description

BPI-572270 is a targeted therapy designed for patients with advanced solid tumors, including colorectal cancer, who harbor specific mutations in RAS genes. This compound belongs to the class of RAS pathway inhibitors, representing a novel approach to target previously "undruggable" RAS mutations that drive tumor growth in approximately 40-50% of colorectal cancers. The drug is currently being evaluated in early-phase clinical development for patients with RAS-mutant tumors who have limited treatment options.

Mechanism of Action

BPI-572270 works by directly targeting mutant RAS proteins or critical downstream effectors in the RAS signaling pathway. The drug disrupts oncogenic RAS signaling cascades that promote uncontrolled cell proliferation, survival, and metastasis in cancer cells harboring RAS mutations.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials